Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
A.O. Smith's Q4 2025 earnings reveal a tale of two stories: revenue that missed expectations but profits that beat them. The water technology leader is leaning into commercial strength and operational discipline to expand margins, even as it braces for a challenging 2026 marked by input cost inflation and persistent softness in its China business.
Bread Financial (NYSE: BFH) posted a mixed fourth quarter, with revenue falling short of expectations but adjusted earnings soaring past estimates. The company credits its disciplined operational focus and expanding product portfolio for the profit strength, even as it navigates a softer top-line environment.
Deere & Company is doubling down on American manufacturing with a new excavator plant and parts center, part of a broader $20 billion commitment. While the move strengthens its long-term industrial narrative, near-term challenges from leadership changes to cyclical market pressures remain in focus.
As the Bank of Canada signals a hold on interest rates, a backdrop of market stability is emerging. This analysis delves into three Canadian penny stocks—Britannia Life Sciences, ROK Resources, and Vision Lithium—that present distinct risk-reward profiles for investors eyeing the junior markets in early 2026.
CNBC's Jim Cramer questions Meta's direction, citing investor skepticism over its AI strategy and spending. Yet strong Q4 earnings reveal a more complex financial picture, sparking debate on Wall Street.
While public attention focuses on flashy AI applications, Baseten is building the critical infrastructure beneath them. Its explosive growth and backing from investors like Nvidia signal its pivotal role in the AI economy's next phase.
A surprise announcement from Google DeepMind triggered a sector-wide sell-off, hitting mobile gaming and ad-tech stocks. Analysts debate the long-term implications for companies like AppLovin.
Despite CEO Elon Musk's bold pronouncements on AI, robotics, and a future of 'Amazing Abundance,' Tesla faces mounting pressure from declining automotive revenues and margins. As the company pivots with massive capital expenditure, investors are left weighing futuristic promises against present-day financial headwinds.
President Trump's dismissal of concerns over the dollar's decline has accelerated a sell-off, sending the greenback to multi-year lows and triggering record-breaking rallies in gold and silver as markets question U.S. currency policy.
Elon Musk is reportedly in discussions to merge his aerospace giant SpaceX with his artificial intelligence venture xAI, aiming to create an integrated powerhouse for deploying AI data centers in orbit, powered by space solar energy.
After a punishing year of underperformance and operational setbacks, Baxter International faces a skeptical analyst community. While some see deep value, the consensus remains firmly on hold as the company navigates product challenges and revised guidance.
Congress has approved $23 billion in initial funding for the ambitious Golden Dome missile defense initiative, yet the absence of a detailed spending blueprint from the Pentagon is stalling progress and clouding investment prospects for 2026.
Morgan Stanley reaffirms its Overweight rating on Nvidia with a $250 price target, citing the company's systemic advantage through its Vera Rubin platform and robust hyperscaler spending, despite acknowledging competitive and demand risks.
Despite a major new Bitcoin purchase, MicroStrategy's stock has plunged to its lowest level since September 2024, as market turbulence and mixed analyst sentiment pressure the crypto-focused software firm ahead of its earnings report.
American Express reported fourth-quarter earnings that narrowly missed analyst forecasts, yet a modest stock decline reflects investor confidence in its robust guidance and the sustained momentum of its high-end cardmember base.
Apple's Q1 earnings showcased blockbuster iPhone revenue of $85.3 billion, yet investor caution prevails amid persistent supply chain constraints and mounting cost pressures that threaten near-term profitability.
